Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind

Qian, Xu; Ren, Rong; Wang, Youfa; Guo, Yan; Fang, Jing; Wu, Zhongdao; Liu, Pei-Long; Han, Tie-Ru

doi:10.1186/s40249-020-00650-1

Cited by 156 publications

(139 citation statements)

References 15 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…This shows the need for clear and definitive leadership to determine staffing levels, organise staff rotas that include extra time for rest and recuperation, and ensure adequate provision of equipment (Ross et al 2020, WHO 2020c Organisational resilience Building resilience in the nursing workforce has long been considered important (Gray 2012), but recently there has been a shift to supporting organisational resilience (HEE 2019). In the current context, organisational resilience is important as the NHS has had little time to prepare for the COVID-19 pandemic (Qian et al 2020). Organisational resilience is defined by McManus et al (2008) as 'a function of an organisation's overall situation awareness, management of keystone vulnerabilities, and adaptive capacity in a complex, dynamic, and interconnected environment'.…”

Section: Resilience In Healthcare Workersmentioning

confidence: 99%

What the COVID-19 pandemic tells us about the need to develop resilience in the nursing workforce

2020

View full text Add to dashboard Cite

Most research on resilience in healthcare systems such as the NHS is based on organisational crises, such as nurse shortages, an ageing workforce and financial restrictions. However, nursing can learn lessons from the past to consider how to become more resilient, particularly considering the 2020 COVID-19 pandemic. This article briefly looks at previous pandemics and disasters that have affected healthcare systems, as well as the 2020 COVID-19 pandemic, and considers how nurse leaders can support staff and show organisational resilience during such emergencies. The article also discusses how nurse leaders can develop their own resilience.

show abstract

Section: Resilience In Healthcare Workersmentioning

confidence: 99%

What the COVID-19 pandemic tells us about the need to develop resilience in the nursing workforce

2020

View full text Add to dashboard Cite

show abstract

“…COVID-19 is caused by SARS-CoV-2, which belongs to the Betacoronavirus genus such as SARS-CoV, and MERS-CoV [3] . SARS-CoV-2 has a lower pathogenicity as compared with SARS-CoV, but has higher pandemic potential [4] , [5] , [6] , [7] . Respiratory droplets, close contact transmission, and aerosol transmission in a relatively closed environment are the major routes of transmission [8] .…”

Section: Introductionmentioning

confidence: 99%

Factors affecting the mortality of patients with COVID-19 undergoing surgery and the safety of medical staff: A systematic review and meta-analysis

Wang¹,

Wu²,

Xu³

et al. 2020

EClinicalMedicine

View full text Add to dashboard Cite

Background The 2019 novel coronavirus disease (COVID-19) can complicate the perioperative course to increase postoperative mortality in operative patients, and also is a serious threat to medical staff. However, studies summarizing the impact of COVID-19 on the perioperative mortality of patients and on the safety of medical staff are lacking. Methods We searched PubMed, Cochrane Library, Embase and Chinese database National Knowledge Infrastructure (CNKI) with the search terms “COVID-19″ or “SARS-CoV-2″ and “Surgery” or “Operation” for all published articles on COVID-19 from December 1, 2019 to October 5, 2020. Findings A total of 269 patients from 47 studies were included in our meta-analysis. The mean age of operative patients with COVID-19 was 50.91 years, and 49% were female. A total of 28 patients were deceased, with the overall mortality of 6%. All deceased patients had postoperative complications associated with operation or COVID-19, including respiratory failure, acute respiratory distress syndrome (ARDS), short of breath, dyspnea, fever, cough, fatigue or myalgia, cardiopulmonary system, shock/infection, acute kidney injury and severe lymphopenia. Patients who presented any or more of the symptoms of respiratory failure, ARDS, short of breath and dyspnea after operation were associated with significantly higher mortality ( r = 0.891, p < 0.001), while patients whose symptoms were presented as fever, cough, fatigue or myalgia only demonstrated marginally significant association with postoperative mortality ( r = 0.675, p = 0.023). Twenty studies reported the information of medical staff infection, and a total of 38 medical staff were infected, and medical staff who used biosafety level 3 (BSL-3) protective equipment did not get infected. Interpretation COVID-19 patients, in particular those with severe respiratory complications, may have high postoperative mortality. Medical staff in close contact with infected patients is suggested to take high level personal protective equipment (PPE). Funding Heilongjiang postdoctoral scientific research developmental fund and the National Natural Science Foundation of China.

show abstract

“…Since then, severe acute respiratory syndrome CoV-2 (SARS-CoV-2), the ethological agent responsible for CoV disease 2019 (COVID- 19), has been detected in 216 countries, areas, or territories, and it has been responsible for over 11,125,245 human cases and 528,204 deaths (https://www.who.int/emergencies/diseases/novel -coronavirus-2019). The unprecedented human health and socioeconomic impact of COVID-19 rivals only that of the "Spanish flu" pandemic, which occurred almost 100 years ago (4)(5)(6)(7)(8). To date, there are no U.S. Food and Drug Administration (FDA)-approved prophylactics (vaccines) or specific therapeutics (antivirals) available for the prevention and treatment, respectively, of SARS-CoV-2-associated COVID-19 disease.…”

mentioning

confidence: 99%

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome

Chiem

Park

et al. 2020

mBio

108

121

View full text Add to dashboard Cite

Infectious coronavirus (CoV) disease 2019 (COVID-19) emerged in the city of Wuhan (China) in December 2019, causing a pandemic that has dramatically impacted public health and socioeconomic activities worldwide. A previously unknown coronavirus, severe acute respiratory syndrome CoV-2 (SARS-CoV-2), has been identified as the causative agent of COVID-19. To date, there are no U.S. Food and Drug Administration (FDA)-approved vaccines or therapeutics available for the prevention or treatment of SARS-CoV-2 infection and/or associated COVID-19 disease, which has triggered a large influx of scientific efforts to develop countermeasures to control SARS-CoV-2 spread. To contribute to these efforts, we have developed an infectious cDNA clone of the SARS-CoV-2 USA-WA1/2020 strain based on the use of a bacterial artificial chromosome (BAC). Recombinant SARS-CoV-2 (rSARS-CoV-2) was readily rescued by transfection of the BAC into Vero E6 cells. Importantly, BAC-derived rSARS-CoV-2 exhibited growth properties and plaque sizes in cultured cells comparable to those of the natural SARS-CoV-2 isolate. Likewise, rSARS-CoV-2 showed levels of replication similar to those of the natural isolate in nasal turbinates and lungs of infected golden Syrian hamsters. This is, to our knowledge, the first BAC-based reverse genetics system for the generation of infectious rSARS-CoV-2 that displays features in vivo similar to those of a natural viral isolate. This SARS-CoV-2 BAC-based reverse genetics will facilitate studies addressing several important questions in the biology of SARS-CoV-2, as well as the identification of antivirals and development of vaccines for the treatment of SARS-CoV-2 infection and associated COVID-19 disease. IMPORTANCE The pandemic coronavirus (CoV) disease 2019 (COVID-19) caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is a major threat to global human health. To date, there are no approved prophylactics or therapeutics available for COVID-19. Reverse genetics is a powerful approach to understand factors involved in viral pathogenesis, antiviral screening, and vaccine development. In this study, we describe the feasibility of generating recombinant SARS-CoV-2 (rSARS-CoV-2) by transfection of a single bacterial artificial chromosome (BAC). Importantly, rSARS-CoV-2 possesses the same phenotype as the natural isolate in vitro and in vivo. This is the first description of a BAC-based reverse genetics system for SARS-CoV-2 and the first time that an rSARS-CoV-2 isolate has been shown to be phenotypically identical to a natural isolate in a validated animal model of SARS-CoV-2 infection. The BAC-based reverse genetics approach will facilitate the study of SARS-CoV-2 and the development of prophylactics and therapeutics for the treatment of COVID-19.

show abstract

Fighting against the common enemy of COVID-19: a practice of building a community with a shared future for mankind

Cited by 156 publications

References 15 publications

What the COVID-19 pandemic tells us about the need to develop resilience in the nursing workforce

What the COVID-19 pandemic tells us about the need to develop resilience in the nursing workforce

Factors affecting the mortality of patients with COVID-19 undergoing surgery and the safety of medical staff: A systematic review and meta-analysis

Rescue of SARS-CoV-2 from a Single Bacterial Artificial Chromosome

Contact Info

Product

Resources

About